Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)

BACKGROUND: Novel combination therapies to overcome anti-PD-1 resistance are required. Enadenotucirev, a tumor-selective blood stable adenoviral vector, has demonstrated a manageable safety profile and ability to increase tumor immune-cell infiltration in phase I studies in solid tumors. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakih, Marwan, Harb, Wael, Mahadevan, Daruka, Babiker, Hani, Berlin, Jordan, Lillie, Tom, Krige, David, Carter, Jo, Cox, Chris, Patel, Minesh, Parfitt, Lola, Powell, Mark, Rosen, Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151977/
https://www.ncbi.nlm.nih.gov/pubmed/37094988
http://dx.doi.org/10.1136/jitc-2022-006561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151977/
https://www.ncbi.nlm.nih.gov/pubmed/37094988
http://dx.doi.org/10.1136/jitc-2022-006561

Ejemplares similares